News: Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

980.15USD
15 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$980.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
$1,079.17
52-wk Low
$750.00

Search Stocks
Select another date:

Sat, Dec 6 2014

High rate of lymphoma patients respond to Bristol-Myers drug: study

- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

High rate of lymphoma patients respond to Bristol-Myers drug-study

Dec 6 - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

FDA declines to approve Bristol-Myers hepatitis drug

- Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.

UPDATE 1-FDA declines to approve Bristol-Myers hepatitis drug

(Adds details on drug, other Bristol-Myers, rival treatments)

FDA declines to approve Bristol-Myers hepatitis drug

Nov 26 - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

RPT-Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

Nov 16 - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

Nov 16 - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

UPDATE 2-Lonza shares drop after revenue forecast cut on weak water business

* Shares fall as much as 8.5 pct (Recasts with fall in shares, adds analyst comments)

Select another date:
Search Stocks